Company: IMCR
Filing Date: 2025-04-04
Form Type: DEF 14A
Source: 0001140361-25-012123
Chunk: 90

Company: Immunocore Holdings plc
Filing Date: 2025-04-04
Form: DEF 14A
Chunk 90
---
 |
| Tina St. Leger(4) |                           |     | Termination without Cause 
 or with Good Reason       |           |     |     364,258 |           |     | —      |           |     | —           |        |     |           6,958 |           |     |   371,216 |
|                   | Termination without Cause 
 or with Good Reason in    
 connection with a CIC     |     |                           |   546,387 |     |             |   364,259 |     |        |         — |     |             | 10,437 |     |                 |   921,083 |     |           |

| (1) | Includes one-and-a-half times target bonus for all the named executive officers (other than Dr. Jallal at two-times target bonus), plus another full year of bonus at target for the year of termination assuming a termination date of December 31, 2024. |

| (2) | The value of the acceleration is based on the excess of the closing price of our ADSs on Nasdaq at December 31, 2024, being $29.50 per ADS, over the exercise price of the options for all in-the-money options, excluding underwater options. |

| (3) | Includes the cost of coverage for the continuation of applicable benefits under COBRA for the U.S.-based named executive officers and continuation of medical and dental benefits for Ms. St. Leger for the applicable period. |

| (4) | Amounts for Ms. St. Leger reflect the conversion from GBP to USD using the exchange rate of GBP 1.00 to USD 1.2781, which represents an average for fiscal year 2024. |

60

TABLE OF CONTENTS

Equity Compensation Plan Information The following table summarizes our equity compensation plan information as of December 31, 2024. Information is included for equity compensation plans approved by our shareholders. We do not have any equity compensation plans not approved by our shareholders.

| Plan Category                             |     |    -a) Number of 
 Securities to be 
      Issued Upon 
      Exercise of 
      Outstanding 
        Options(1 |     |     -b) Weighted 
 Average Exercise 
         Price of 
      Outstanding 
        Options(1 |     |         -c) Number of 
  Securities Remaining 
  Available for Future 
 Issuance Under Equity 
    Compensation Plans 
 (Excluding Securities